1.Language Learning Strategy Training in Classroom
Journal of Zhejiang Chinese Medical University 2006;0(04):-
Based on the analysis of Language Learning Strategies of foreign language learners and their characteristics,this paper illuminates that training on Language Learning Strategies in regular language classes helps foreign language learners become successful and independent learners.
2.Role of TRAF2 in AP-1 signaling pathway of human B cells
Basic & Clinical Medicine 2006;0(05):-
Objective To investigate the role of TRAF2 in AP-1 signaling pathway of human B cells.Methods Human Ramos B cells were transfected with plasmids expressing YFP fusion wild type TRAF2(YFP-WT-TRAF2) or YFP fusion dominant-negative TRAF2(DN-TRAF2),or transfected with shRNA-TRAF2 and control shRNA plasmid.After incubation overnight,cells were either sorted with flowcytometry or screened by antibiotics G418.Activation of AP-1 pathway,including phosphorylation of ERK,JNK and P38,as well as nuclear translocation of AP-1 subunits were detected by western blot and ELISA.Results Overexpression of WT-TRAF2 selectively induced activition of MAPK by phosphorylation of ERK and P38,and further induced nuclear translocation of C-FOS.Moreover,both overexpression of DN-TRAF2 and transfection of shRNA-TRAF2 inhibited phosphorylation of ERK and P38,and nuclear translocation of C-FOS.Conclusion TRAF2 selectively activates some kinases in CD40 mediated AP-1 signaling pathway,and plays an important role in AP-1 activation.
3.B cell depletion in treating rheumatoid arthritis
Basic & Clinical Medicine 2006;0(09):-
B cells play a central role in the pathogenesis of rheumatoid arthritis(RA) through multiple mechanisms.Clinical trials have demonstrated that anti-CD20 monoclonal antibody(Rituximab) is effective and safe to treat refractory RA through depletion of B cells.Rituximab is now approved by FDA for use concurrently with methotrexate to treat RA in patients who have an inadequate response to one or more tumor necrosis factor inhibitors.
4.Clinical study of Tanshinone ⅡA for treatment on acute cerebral infarction
Journal of Clinical Neurology 1997;0(06):-
Objective To investigate the efficacy and mechanism of Tanshinone ⅡA for treatment on acute cerebral infarction(ACI). Methods 104 patients with ACI were randomly divided into Tanshinone group (50 cases) and control group (54 cases),and were treated with conventional therapy. While,Tanshinone ⅡA was added by intravenous drop in Tanshinone group for 2 weeks. Neurological functional deficit scores,Barthel index(BI) were observed,the levels of serum superoxide dismutas(SOD),lipid peroxide (LPO) and malondialdehyde (MDA) were detected pre and post treatment. The efficacy was compared in the two groups.Results After 2 weeks of treatment,the score of National institute of health stroke scale (NIHSS) was decreased,BI was increased,the level of serum SOD was increased,the levels of serum LPO and MDA were decreased in the two groups. Compared with those in pre treatment,the changes of all the targets were significantly different (all P
5.Qualitative study on psychological pressures of emergency nurses assigned to EICU
Modern Clinical Nursing 2013;(1):14-16
Objective To investigate psychological pressure sources of emergency nurses who were assigned to emergency intensive care unit(EICU)and put forward countermeasures.Methods We collected data by phenomenological method of qualitative study.Thirteen nurses who had worked in EICU for at least six months were interviewed.The collected data we analyzed by Colaizzi analysis method.Result The psychological pressure had its sources from 4 main aspects: nursing skills,increasing labor intensity,communications with patients and shortage of staff.Conclusion Nursing administration should actively take measures to relieve the psychological pressures of the emergency nurses who were assigned to EICU so as to improve the nurses’working enthusiasm and the nursing quality of EICU.
6.Cost-Effectiveness Analysis of Two Drug Combination Schemes for Acute Episode of Chronic Obstructive Pulmonary Disease
Yu'E ZHANG ; Xuan JIANG ;
China Pharmacy 2005;0(22):-
0.05),respectively and the cost-effectiveness ratios were 689 and 1 202 respectively.CONCLUSION:The treatment group was superior to as compared with the control group.
7.Advances inHelicobacter pylori infection in children
Journal of Clinical Pediatrics 2015;(4):391-395
Helicobacter pylori (H.pylori) infection is the most important pathogenic microorganisms associated with the development of chronic gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue lymphoma (MALT) in children. H.pylori infection may occur in early childhood and last a lifetime even directly affecting the health of adulthood unlessH.pylori infection was eradicated. This article aims to review the infection condition, infection pathway and immunological characteristics ofH.pylori and its relationship with extragastroduodenal diseases in children.
8.Role of dopamine receptor in intestinal mucosal barrier change after brain injury in rats
Chinese Journal of Trauma 2014;30(7):735-739
Objective To investigate the effect of dopamine receptor in intestinal mucosal barrier function after brain injury in rats.Methods Twenty-four rats were allocated to control group,brain injury group,dopamine receptor group,and dopamine antagonist group according to the random number table,with 6 rats per group.Feeney' s weight-drop model was introduced to generate rat models of brain injury.Intestinal mucosal specimens were harvested at postoperative 7 days to evaluate intestinal mucosal morphology by HE staining,expressions of dopamine receptor D1 (DRD1) and dopamine receptor D2 (DRD2) by immunohistochemistry,and mRNA and protein expressions of DRD1 and DRD2 by real-time PCR and Western blot.Meantime,urinary samples were collected to measure lactulose to mannitol ratio (L/M) by high performance liquid chromatography (HPLC).Results Intestinal villus integrity was disrupted in brain injury group and dopamine receptor group when compared to control group,but it remained relatively intact in dopamine antagonist group.Ratio of L/M in brain injury group and dopamine receptor group was similar (0.192 ± 0.080 vs 0.183 ± 0.090,P > 0.05),far higher than 0.037 ± 0.008 in control group (P <0.01),but it was reversed in dopamine antagonist group (0.071 ± 0.008,P < 0.01).Real-time PCR showed DRD1 and DRD2 mRNAs expressed in brain injury group and dopamine receptor group were similar (0.764 ± 0.074 vs 0.718 ± 0.065,0.439 ± 0.051 vs 0.408 ± 0.090,P > 0.05),far higher than 0.189 ± 0.008 and 0.076 ± 0.011 in control group (P < 0.01),but both lowered in dopamine antagonist group (0.386 ± 0.071,0.270 ± 0.092,P < 0.01).estern blot analysis showed DRD1 and DRD2 proteins in brain injury group and dopamine receptor group were similar,but both were far higher when compared to control group (P < 0.01).Conclusion Impaired intestinal mucosal barrier may be relate to the up-regulated dopamine receptor in intestinal mucosa after brain injury in rats.
9.Diagnosis and therapy status of mesenteric venous thrombosis
Chinese Journal of Interventional Imaging and Therapy 2009;6(6):590-593
Mesenteric venous thrombosis (MVT) is a kind of rare intestinal anemic disease.Because the clinical manifestations of MVT do not have high specificity,early diagnosis is difficult.In recent years,with huge progress of medical imaging technology,particularly the clinical application of spiral CT and MRI,the early diagnosis of MVT became possible.With the development of interventional therapies,especially the maturity of the interventional treatment technology such as mesenteric artery perfusion with papaverine,thrombectomy and thrombolysis via percutaneous transhepatic portal vein and so on,MVT mortality rate reduced greatly.The diagnosis and therapy status of MVT were reviewed in this article.
10.Progress in treatment of systemic lupus erythematosus.
Chinese Journal of Pediatrics 2013;51(3):161-164
Antirheumatic Agents
;
administration & dosage
;
therapeutic use
;
Biological Products
;
administration & dosage
;
therapeutic use
;
Drug Therapy, Combination
;
Evidence-Based Medicine
;
Glucocorticoids
;
administration & dosage
;
therapeutic use
;
Humans
;
Immunosuppressive Agents
;
administration & dosage
;
therapeutic use
;
Lupus Erythematosus, Systemic
;
drug therapy
;
pathology
;
Lupus Nephritis
;
drug therapy
;
pathology
;
Severity of Illness Index